About Beta-1,3-glucosyltransferase
Beta-1,3-glucosyltransferase (B3GLCT) is a protein
from Homo sapiens identified by UniProt accession
Q6Y288, 498 residues long.
MolForge cross-references it against 0 known binders and
149 disease associations.
Target properties
| Protein name | Beta-1,3-glucosyltransferase |
| UniProt accession | Q6Y288 |
| Gene | B3GLCT |
| Organism | Homo sapiens |
| Length | 498 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (149)
Diseases linked to this target (Open Targets).
- Peters plus syndrome · score 0.81
- genetic disorder · score 0.45
- self reported educational attainment · score 0.42
- blood protein measurement · score 0.38
- heel bone mineral density · score 0.37
- Orofacial cleft · score 0.37
- mathematical ability · score 0.36
- age-related macular degeneration · score 0.36
- unipolar depression · score 0.33
- gastroesophageal reflux disease · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6Y288-F1 | alphafold | PREDICTED | 86.71 | — |
Amino-acid sequence (498 residues)
MRPPACWWLL APPALLALLT CSLAFGLASE DTKKEVKQSQ DLEKSGISRK NDIDLKGIVF VIQSQSNSFH AKRAEQLKKS ILKQAADLTQ ELPSVLLLHQ LAKQEGAWTI LPLLPHFSVT YSRNSSWIFF CEEETRIQIP KLLETLRRYD PSKEWFLGKA LHDEEATIIH HYAFSENPTV FKYPDFAAGW ALSIPLVNKL TKRLKSESLK SDFTIDLKHE IALYIWDKGG GPPLTPVPEF CTNDVDFYCA TTFHSFLPLC RKPVKKKDIF VAVKTCKKFH GDRIPIVKQT WESQASLIEY YSDYTENSIP TVDLGIPNTD RGHCGKTFAI LERFLNRSQD KTAWLVIVDD DTLISISRLQ HLLSCYDSGE PVFLGERYGY GLGTGGYSYI TGGGGMVFSR EAVRRLLASK CRCYSNDAPD DMVLGMCFSG LGIPVTHSPL FHQARPVDYP KDYLSHQVPI SFHKHWNIDP VKVYFTWLAP SDEDKARQET QKGFREEL
Explore Beta-1,3-glucosyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets